| Uveitis
Iluvien vs Yusimry
Side-by-side clinical, coverage, and cost comparison for uveitis.Deep comparison between: Iluvien vs Yusimry with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYusimry has a higher rate of injection site reactions vs Iluvien based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yusimry but not Iluvien, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Iluvien
Yusimry
At A Glance
Intravitreal injection
Corticosteroid
SC injection
Every 1-2 weeks
TNF-alpha inhibitor
Indications
- Diabetic Retinopathy
- Uveitis
- Rheumatoid Arthritis
- Juvenile arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
Dosing
Diabetic Retinopathy, Uveitis Single 0.19 mg (190 mcg) fluocinolone acetonide intravitreal implant injected under aseptic conditions via a preloaded single-use applicator; optimal placement is inferior to the optic disc and posterior to the equator, with needle entry 4 mm inferotemporal from the limbus.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; in Rheumatoid Arthritis without concomitant MTX, may increase to 40 mg every week or 80 mg every other week.
Juvenile arthritis 40 mg SC every other week for patients 2 years of age and older weighing 30 kg or greater.
Crohn Disease, Ulcerative Colitis 160 mg SC on Day 1 (or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29.
Psoriasis vulgaris, Uveitis Initial 80 mg SC, then 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1 (or split over two consecutive days), 80 mg on Day 15, then 40 mg weekly or 80 mg every other week starting Day 29.
Contraindications
- Active or suspected ocular or periocular infections, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases
- Glaucoma with cup to disc ratio greater than 0.8
- Known hypersensitivity to any components of ILUVIEN
—
Adverse Reactions
Most common (>=1%) Cataract, increased intraocular pressure, myodesopsia, eye pain, conjunctival haemorrhage, posterior capsule opacification, eye irritation, vitreous detachment, conjunctivitis, corneal oedema, ocular hyperaemia, anemia, headache, renal failure, pneumonia
Serious Optic nerve damage, visual acuity and field defects, secondary ocular infections including herpes simplex, perforation of the globe where there is thinning of the cornea or sclera
Postmarketing Drug administration error, drug ineffectiveness
Most common (>=5%) Injection site reactions, upper respiratory infection, sinusitis, headache, rash, nausea, abdominal pain, back pain, urinary tract infection, hyperlipidemia, hypercholesterolemia, accidental injury.
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity, liver enzyme elevations.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, systemic vasculitis, deep vein thrombosis.
Pharmacology
Fluocinolone acetonide is a synthetic corticosteroid that inhibits inflammatory responses by blocking phospholipase A2 via lipocortins, suppressing biosynthesis of prostaglandins and leukotrienes and reducing edema, leukocyte migration, capillary proliferation, and fibroblast proliferation.
TNF-alpha antagonist; adalimumab-aqvh is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Iluvien
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Yusimry
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Iluvien
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Yusimry
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Iluvien
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Yusimry
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25
Iluvien CoPay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Yusimry.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IluvienView full Iluvien profile
YusimryView full Yusimry profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.